Hims & Hers Health (NYSE:HIMS) Given New $33.00 Price Target at Truist Financial

Hims & Hers Health (NYSE:HIMS - Get Free Report) had its price objective dropped by equities researchers at Truist Financial from $39.00 to $33.00 in a report released on Thursday,Benzinga reports. The firm currently has a "hold" rating on the stock. Truist Financial's price target suggests a potential upside of 16.98% from the company's previous close.

Several other equities analysts have also recently issued reports on the company. Citigroup restated a "sell" rating on shares of Hims & Hers Health in a research report on Wednesday, April 2nd. Needham & Company LLC upped their price target on Hims & Hers Health from $31.00 to $61.00 and gave the stock a "buy" rating in a research note on Tuesday, February 25th. BTIG Research initiated coverage on Hims & Hers Health in a report on Tuesday, January 7th. They set a "buy" rating and a $35.00 price target for the company. Bank of America boosted their price objective on shares of Hims & Hers Health from $21.00 to $22.00 and gave the company an "underperform" rating in a research note on Tuesday, March 18th. Finally, Leerink Partners raised their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research note on Tuesday, February 25th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $38.25.

Remove Ads

Hims & Hers Health Stock Performance

NYSE HIMS traded up $0.98 on Thursday, reaching $28.21. The stock had a trading volume of 13,955,484 shares, compared to its average volume of 15,141,391. The stock has a market cap of $6.27 billion, a P/E ratio of 64.12 and a beta of 1.65. Hims & Hers Health has a 12-month low of $11.20 and a 12-month high of $72.98. The business's 50-day moving average price is $38.75 and its 200 day moving average price is $30.46.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. On average, sell-side analysts predict that Hims & Hers Health will post 0.29 earnings per share for the current year.

Insider Buying and Selling

In other Hims & Hers Health news, CEO Andrew Dudum sold 128,127 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total transaction of $7,465,960.29. Following the completion of the transaction, the chief executive officer now owns 97,687 shares of the company's stock, valued at approximately $5,692,221.49. This trade represents a 56.74 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Soleil Boughton sold 54,153 shares of the business's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $29.90, for a total value of $1,619,174.70. Following the completion of the transaction, the insider now directly owns 165,650 shares of the company's stock, valued at approximately $4,952,935. This trade represents a 24.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 824,303 shares of company stock worth $31,376,661 in the last quarter. Company insiders own 17.71% of the company's stock.

Institutional Trading of Hims & Hers Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Farallon Capital Management LLC raised its position in shares of Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after buying an additional 8,364,000 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its position in Hims & Hers Health by 192.0% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after acquiring an additional 4,145,305 shares during the last quarter. Vanguard Group Inc. grew its stake in Hims & Hers Health by 11.1% in the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after acquiring an additional 2,020,722 shares during the period. Yong Rong HK Asset Management Ltd acquired a new position in Hims & Hers Health in the 4th quarter valued at $41,104,000. Finally, Renaissance Technologies LLC lifted its stake in shares of Hims & Hers Health by 29.0% during the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock worth $168,079,000 after purchasing an additional 1,562,302 shares during the period. Hedge funds and other institutional investors own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.